Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIB104
- Development stage
- Unknown
- Lead developer
- Noile-Immune Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NIB104 is an early preclinical **CAR-T cell therapy** being developed by Noile-Immune as part of the company's in-house oncology pipeline. The program is described as a CAR-T product directed against an **undisclosed antigen**, and it is likely intended to leverage Noile-Immune's PRIME CAR-T platform to drive antigen-specific T-cell mediated cytotoxicity against tumor cells. Publicly available pipeline information does not disclose the precise target antigen, tumor indication, dosing route, or manufacturing details, but the asset is shown as a distinct in-house preclinical program separate from Noile-Immune's GM2, GPC3, and mesothelin-directed CAR-T candidates.
- Other names
- NIB104 Noile-Immune undisclosed CAR-T cell therapyNIB-104 Noile-Immune undisclosed CAR-T cell therapyNIB 104 Noile-Immune undisclosed CAR-T cell therapy
Beyond the preview
Go deeper on NIB104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIB104.